scholarly journals Ensemble forecasting of a continuously decreasing trend in bladder cancer incidence in Taiwan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bo-Yu Hsiao ◽  
Shih-Yung Su ◽  
Jing-Rong Jhuang ◽  
Chun-Ju Chiang ◽  
Ya-Wen Yang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Incidence ◽  
Total Population ◽  
Incidence Rates ◽  
World Health ◽  
Cohort Model ◽  
Incidence Trends ◽  
Health Organization ◽  
Cancer Incidence Rates ◽  
Population Numbers

AbstractBladder cancer is one of the most common malignancies involving the urinary system of about 1.65 million cases worldwide. To attain the 25 by 25 goal set by the World Health Organization (25% reduction in non-communicable diseases between 2015 and 2025), developing strategies to reduce cancer burdens is essential. The data of the study comprised the age-specific bladder cancer cases and total population numbers from age 25 to 85 and above from 1997 to 2016 in Taiwan. An ensemble age–period–cohort model was used to estimate bladder cancer incidence trends and forecast the trends to 2025. For men, the projected age-standardized incidence rates per 100,000 people in 2020 and 2025 are 13.0 and 10.4, respectively, with a 16.1% and 32.9% decrease projected from 2016 to 2020 and 2025, respectively. For women, the projected age-standardized incidence rates per 100,000 people in 2020 and 2025 are 4.7 and 3.7, respectively, with a 16.1% and 33.9% decrease projected from 2016 to 2020 and 2025, respectively. The age-specific bladder cancer incidence rates demonstrated a consistently downward trend after 2003 for all ages and both sexes. This study projects that the incidence rates of bladder cancer in Taiwan will continue to decrease, and more than a 25% reduction can be achieved from 2016 to 2025.

Proximity to oil refineries and risk of bladder cancer: A population-based analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4538-4538
Author(s):  
Tamer Dafashy ◽  
Daniel Phillips ◽  
Mohamed Danny Ray-Zack ◽  
Preston Kerr ◽  
Yong Shan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Incidence ◽  
Census Data ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Oil Refinery ◽  
Oil Refineries ◽  
Background Exposure ◽  
Cancer Incidence Rates

4538 Background: Exposure to aromatic amines is a risk factor for bladder cancer. Incidence rates according to proximity to oil refineries are largely unknown. We sought to determine proximity of oil refineries and bladder cancer incidence in the State of Texas which is home to the largest number of oil refineries in the United States. Methods: We used the Texas Cancer Registry database to identify patients diagnosed with bladder cancer from January 1, 2001 to December 31, 2014. The U.S. census data from 2010 was used to ascertain overall population size, age and sex distributions. Heat maps of the 28 active oil refineries in Texas were developed. Incidence of bladder cancer were compared according to proximity ( < 10 vs. ≥ 10 miles) to an oil refinery. Risk ratios were adjusted using a Poisson regression model. Results: A total of 45,517 incident bladder cancer cases were identified of which 5,501 cases were within 10 miles of an oil refinery. In adjusted analyses, bladder cancer risk was significantly greater among males vs. females (Relative Risk (RR) 3.41, 95% Confidence Interval (CI), 3.33-3.50), and greater among people living within 10 miles from an oil refinery than those living outside a 10-mile radius from an oil refinery (RR 1.19, 95% CI, 1.08-1.31). Conclusions: People living within 10 miles from oil refineries were at greater risk for bladder cancer. Further research into exposure to oil refineries and bladder cancer incidence is warranted.

scholarly journals Ovarian Cancer Incidence Trends in Relation to Changing Patterns of Menopausal Hormone Therapy Use in the United States

2013 ◽  
Vol 31 (17) ◽  
pp. 2146-2151 ◽  
Author(s):  
Hannah P. Yang ◽  
William F. Anderson ◽  
Philip S. Rosenberg ◽  
Britton Trabert ◽  
Gretchen L. Gierach ◽  
...  
Keyword(s):  
United States ◽  
Ovarian Cancer ◽  
Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Ovarian Cancer Risk ◽  
Histologic Subtype ◽  
Incidence Trends ◽  
Cancer Incidence Rates

Purpose After a report from the Women's Health Initiative (WHI) in 2002, a precipitous decline in menopausal hormonal therapy (MHT) use in the United States was linked to a decline in breast cancer incidence rates. Given that MHT use is also associated with increased ovarian cancer risk, we tested whether ovarian cancer incidence rates changed after 2002. Methods Using the North American Association of Central Cancer Registries database (1995 to 2008; N = 171,142 incident ovarian cancers), we applied standard analytic approaches and age-period-cohort (APC) models to estimate ovarian cancer incidence rate changes before (1995 to 2002) and after (2003 to 2008) the WHI report. Results Among women age ≥ 50 years, age-standardized ovarian cancer incidence declined by 0.8% per year (95% CI, −1.8% to −0.5% per year) before the WHI announcement; after the WHI report, the rate declined by 2.4% per year (95% CI, −2.5% to −2.2% per year). APC models confirmed an accelerated decline in ovarian cancer incidence after the WHI report, adjusted for age and birth cohort effects. This sudden change was notable among women most likely to have used MHT (ie, women age 50 to 69 years, white women, and residents of regions with highest MHT prescription frequency). The largest changes were found for the endometrioid histologic subtype. Conclusion After a marked reduction in MHT use around 2002, ovarian cancer incidence rates demonstrated an accelerated decline, with the largest changes for endometrioid carcinomas. This strong temporal association, although not proving a causal role of hormones in ovarian carcinogenesis, suggests that future analytic research supporting cancer control efforts should clarify the role of hormonal exposures on the development and behavior of subtypes of ovarian cancer.

Age-Specific Trend and Birth Cohort Effect on Different Histologic Types of Uterine Corpus Cancers

2021 ◽  
Author(s):  
Yi-Jou Tai ◽  
Chun-Ju Chiang ◽  
Ying-Cheng Chiang ◽  
Chia-Ying Wu ◽  
Wen-Chung Lee ◽  
...  
Keyword(s):  
Birth Cohort ◽  
Cancer Incidence ◽  
Incidence Rates ◽  
Endometrioid Carcinoma ◽  
Birth Cohorts ◽  
Cancer Specific Survival ◽  
Uterine Corpus ◽  
Incidence Trends ◽  
Histologic Types ◽  
Cancer Incidence Rates

Abstract To evaluate the uterine corpus cancer incidence rates, age-specific trends and birth cohort patterns by different histologic types. From the Taiwan Cancer Registry, we identified women with a primary diagnosis of uterine corpus cancer (n=28 769) from1998 to 2017. We analyzed the incidences, stages of disease at diagnosis and prognostic factors in endometrioid and non-endometrioid carcinoma. During the study period, uterine corpus cancer incidence rates increased over time from 5.3 to 15.21 per 100 000 woman-years. Incidence trends for endometrioid carcinoma increased in all age groups and the rise was steeper in women age 40 years and younger. For non-endometrioid carcinomas, incidence rates increased in women over 50 years. Women diagnosed after 2013 had significantly better cancer-specific survival (CSS) (hazard ratio [HR] =0.81, 95% confidence interval [CI] 0.73-0.89) compared with those at the period of 2009-2012. CSS also improved in stage I (HR=0.81, 95% CI 0.49-0.63) and stage III (HR 0.90, 95% CI 0.58-0.72) endometrioid carcinomas after 2013. Whereas CSS remained unchanged for non-endometrioid carcinomas. We found the incidences of both endometrioid and non-endometrioid carcinomas continued to increase among contemporary birth cohorts. Etiologic research is mandatory to explain the causes for these trends.

scholarly journals SUN-302 Incidence Trends in Lung and Gastroenteropancreatic Neuroendocrine Neoplasms

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Heba Alwan ◽  
Stefano La Rosa ◽  
Peter Kopp ◽  
Simon Germann ◽  
Manuela Maspoli-Conconi ◽  
...  
Keyword(s):  
Cancer Registries ◽  
Population Based ◽  
Incidence Rates ◽  
World Health ◽  
International Agency ◽  
Neuroendocrine Neoplasms ◽  
Incidence Trends ◽  
Time Period ◽  
Well Differentiated ◽  
Health Organization

Abstract Abstract Introduction The incidence of neuroendocrine neoplasms (NENs) seems to increase worldwide. However, long-term, population-based data that consider differentiation levels are sparse. Objective To evaluate the incidence trend of lung and gastroenteropancreatic (GEP) NENs according to the latest International Agency for Research on Cancer/World Health Organization classification over a 41-year time period in two Swiss regions. Methods All cases of lung and GEP NENs recorded in the Vaud and Neuchâtel Cancer Registries from 1976–2016 were included. NENs were stratified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Changes in annual age-standardized incidence rates were calculated for lung and GEP NETs and NECs by sex. Results There were 4141 patients diagnosed with NENs, of which 65% were men. The incidence of lung NETs did not reveal any statistically significant trend in men, but increased in women by 4.9%/year between 1976–2016. The incidence of lung NECs in men decreased significantly by 2.6%/year from 1985–2016 whereas the incidence of lung NECs in women increased significantly between 1976–1998 by 6%/year. For GEP NETs, a steady annual increase in incidence occurred between 1976–2016 with a magnitude of 1.7% in men and 1.3% in women. No trend in incidence of GEP NECs was found for both sexes. Conclusions The incidence trends of lung NECs in men and women parallel changes in smoking prevalence in the population whereas causes of the increase in incidence of GEP NETs are not fully understood. Our study supports the importance of evaluating the epidemiology of NENs by their differentiation level.

Bladder cancer incidence rates and trends in young adults aged 20-39 years

2020 ◽  
Vol 38 (12) ◽  
pp. 934.e11-934.e19
Author(s):  
Carlotta Palumbo ◽  
Angela Pecoraro ◽  
Giuseppe Rosiello ◽  
Stefano Luzzago ◽  
Marina Deuker ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Young Adults ◽  
Cancer Incidence ◽  
Incidence Rates ◽  
Cancer Incidence Rates

scholarly journals 40 Years of Change in Age- and Stage-Specific Cancer Incidence Rates in US Women and Men

2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Rebecca D Kehm ◽  
Wan Yang ◽  
Parisa Tehranifar ◽  
Mary Beth Terry
Keyword(s):  
Breast Cancer ◽  
Young Adults ◽  
Cancer Incidence ◽  
Age Groups ◽  
Incidence Rates ◽  
Permutation Testing ◽  
Incidence Trends ◽  
Specific Cancer ◽  
Old Men ◽  
Cancer Incidence Rates

Abstract Background Studies have documented a temporal increase in incidence for several cancers in US young adults aged 25 to 39-years, including noncardia gastric cancer, colorectal cancer, and distant-stage breast cancer. To further characterize trends in young adults, we assessed age-specific and stage-specific incidence trends from 1975 to 2015, overall (all malignant cancers combined), and for 18 and 16 cancer sites in women and men, respectively. Methods We used US population-based data from the Surveillance, Epidemiology, and End Results Program to obtain overall and site-specific cancer incidence rates by sex and age group. We individually analyzed cancer sites with an incidence rate of at least 5 per 100 000 in 2015, accounting for greater than 90% of all cancer diagnoses. We estimated annual percent changes (APCs) using segment log-linear regression performed with joinpoint software; multiple permutation testing was used to identify inflection points. We forecasted overall cancer incidence through 2030 using age-period-cohort regression models. Results Based on trends occurring after the most recent joinpoint inflection point, overall cancer incidence increased by 1.15% (95% CI = 1.01% to 1.28%) per year in 25- to 39-year-old women and by 0.46% (95% CI = 0.17% to 0.75%) per year in 25- to 39-year-old men; APCs were of much lower magnitude in the older age groups (eg, 70- to 84-year-old women APC = −0.31%, 95% CI = −0.42% to −0.20%). We forecasted that overall cancer incidence will increase by an additional 11% by 2030 in 25- to 39-year-old women, and by an additional 12% in 25- to 39-year-old men. Ten of the 18 cancers assessed in 25- to 39-year-old women and 7 of the 16 cancers in 25- to 39-year-old men have been statistically significantly increasing over time. We found that the increase in incidence for young adults is stage specific for some cancers (eg, only nonlocalized breast cancer has increased in 25- to 39-year-old women). Conclusion Cancer incidence is increasing in young adults, particularly in young women.

scholarly journals Rising and Falling Trends in Incidence Rates of Vulvar and Vaginal Cancers in the United States, 2000-2016

2020 ◽  
Author(s):  
Yang-yang Yue ◽  
Wei-li Zhou ◽  
Dong-mei Pei
Keyword(s):  
Cancer Incidence ◽  
Vulvar Cancer ◽  
Relative Survival ◽  
Incidence Rates ◽  
Histological Type ◽  
Vaginal Cancer ◽  
Cancer Rate ◽  
Incidence Trends ◽  
Cancer Rates ◽  
Cancer Incidence Rates

Abstract Background: Few studies focus on incidence trends in vulvar and vaginal by histological type, race, age, and region. We aimed to evaluate the temporal incidence trends and survival for the two cancers.Methods: Cases with primary vulvar or vaginal carcinoma from 2000-2016 were identified from the Surveillance, Epidemiology, and End Results 18 registries. Annual percent change (APC) and average APC (AAPC) were calculated to evaluated trends. Relative survival was estimated to compare survival outcomes.Results: Vulvar cancer incidence rates were highest among non-Hispanic whites (20.9 per 1,000,000 person-years) and in the Midwest (27.7), while vaginal cancer rates were highest among non-Hispanic blacks (8.2) and in the South (6.7). Overall, vulvar cancer rate increased 0.4% annually (AAPC, 0.4%; 95% CI, 0.1% to 0.6%), but vaginal cancer rate decreased 1.4% annually (AAPC, -1.4%; 95% CI, -2.0% to -0.5%). The increased vulvar cancer rate was only observed for squamous cell carcinoma (APC, 1.0%), while the decreased vaginal cancer rate was only observed for other malignancies (APC, -1.7%). Vulvar cancer rates increased only among whites (APC, 1.2%), but vaginal cancer rates decreased only among whites (AAPC, -1.3%) and Asians (APC, -2.7%). Vulvar cancer rates increased among patients aged 50-59 (APC, 1.1%), 60-69 (APC, 1.3%), and 70-79 (APC, 1.2%) years, while vaginal cancer rates decreased among patients aged 50-59 (APC, -1.4%) and 80 (APC, -1.4%) years or older. Overall, whites had the highest five-year relative survival for both vulvar (72.22%) and vaginal (49.03%) cancers. Conclusion: There were profound disparities in vulvar and vaginal cancer incidence rates attributable to histological type, race, age, and region. The increased vulvar cancer rates and the declined vaginal cancer rate highlights the importance of further studies to investigate the reason for the disparities.

Sign in / Sign up

Export Citation Format

Share Document